Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Investor Presentation (October 2026)
28 slides from Vivani Medical's investor presentation, October 2026
Slide 1: Vivani Medical, Inc. – Guaranteed Adherence. Better Outcomes.
Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. www.vivani.com October 2026
Slide 2: Disclaimers
Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe ha
Slide 3: Vivani Medical, Inc.
Vivani Medical, Inc. Clinical stage innovator uniquely positioned to address the future Nasdaq: VANI challenges and opportunities of an evolving obesity market Cash runway expected to Our focus: Enhance patient outcomes and GLP-1 market uptake in chronic fund current operating plan, diseases via uni
Slide 4: NPM-139: Our lead program, designed to solve the problem of patient adherence to GLP-1 therapy
NPM-139: Our lead program, designed to solve the problem of patient adherence to GLP-1 therapy We are developing a once- or twice-yearly semaglutide implant for chronic weight management in obese or overweight patients FDA-approved GLP-1 products Based on real-world adherence and generated $132B in
Slide 5: Persistence and adherence are critical to securing desired long-term health outcomes
Persistence and Large Retrospective Cohort Study* (N=1,911) adherence are critical 6 months 12 months to securing desired long-term health 100% outcomes Percent Remaining on Therapy 75% Persistence data comparing obesity therapies suggest room for improvement across the board, 50% including for sema
Slide 6: GLP-1 (semaglutide) discontinuation leads to rapid hunger-induced weight rebound
GLP-1 (semaglutide) discontinuation leads to rapid hunger- induced weight rebound Sudden semaglutide withdrawal produces immediate rebound hunger, leading to rapid weight regain mediated by greater food consumption STEP 1 Extension: Semaglutide Withdrawal From Novo Nordisk Wegovy® Clinical Program 6
Slide 7: Large pharma is investing heavily in extending GLP-1 dosing intervals
Large pharma is investing heavily in extending GLP-1 dosing intervals Approved GLP-1s are Recent investments target Vivani is developing once- or dosed daily or weekly. monthly and beyond. twice-yearly dosing APPROVED TODAY WHERE PHARMA IS INVESTING (SELECT TRANSACTIONS) VIVANI NANOPORTAL (IN DEVELO
Slide 8: Patient and prescriber market research signals strong adoption potential for an ultra-long-acting GLP-1 implant
Patient and prescriber market research signals strong adoption potential for an ultra-long-acting GLP-1 implant Currently on a GLP-1 therapy (n=324) Patient market research 56% of GLP-1 patients responded “likely” 11% 33% 42% 14% or “definitely” to get a GLP-1 implant if FDA approved, prescriber rec
Slide 9: Contraception analog supports strong adoption potential for an ultra-long-acting GLP-1 implant
Contraception analog supports strong adoption potential for an ultra-long-acting GLP-1 implant THE CONTRACEPTION MARKET: AN ANALOG FOR GLP -1s Both require chronic dosing, with options spanning daily oral pills and long-acting implants. Among U.S. women ages 15–49 using a prescription contraceptive
Slide 10: Company pipeline utilizing NanoPortal platform
Company pipeline utilizing NanoPortal platform If approved, Vivani products would provide a differentiated ultra long-acting option for patients Indication Feasibility Preclinical Clinical Obesity/Weight NPM-139 Management semaglutide Obesity/Weight Next-generation Management incretins* Vivani Obesi
Slide 11: Good things come in small packages
Good things come in small packages 01 GLP-1 implant & applicator 02 NanoPortal device elements 03 NanoPortal technology ✔ Biocompatible materials ✔ Nanotube pore size is precisely tunable to achieve near-constant release ✔ Designed to assure adherence profiles ✔ Long-term delivery ✔ Stable and tunab
Slide 12: NanoPortal delivers smooth, near-constant drug release
NanoPortal delivers smooth, near-constant drug release Day 1 timepoint includes cumulative release over the first day including a separately measured 1st hour of release, which was ~7 µg for the high-dose and ~4 µg for the low- dose. Values are mean ± SD. *Release-rates include exenatide and related
Slide 13: In vitro and in vivo performance of 12-week GLP-1 implant configuration
In vitro and in vivo performance of 12-week GLP-1 implant configuration In vitro release-rate of exenatide implant (n=17). Individual values are In vivo pharmacokinetics of 12-week exenatide implant and sham implant included for each timepoint. Each week consists of two 24-hour intervals and a in hi
Slide 14: Preclinical GLP-1 NanoPortal implant is associated with durable body weight effects
Preclinical GLP-1 NanoPortal implant is associated with durable body weight effects A B Weight difference from control in healthy Sprague-Dawley Rats. % weight change from baseline for a single administration of an exenatide implant (~320 nmol/kg/day) corrected to control (vehicle implant). (A) All
Slide 15: GLP-1 NanoPortal implant reduced liver fat by 82% in preclinical study
GLP-1 NanoPortal 35.0 implant reduced liver 30.0 fat by 82% in preclinical study 25.0 Liver fat (% 20.0 Area) 15.0 10.0 5.0 Liver fat reduction in high fat diet-induced obese mice. Liver fat % area for exenatide 0.0 Sham Implant Exenatide Implant implant vs sham implant 12 weeks after a single (n=7)
Slide 16: First-in-human GLP-1 NanoPortal clinical trial: LIBERATE-1
First-in-human GLP-1 NanoPortal clinical trial: LIBERATE-1 Primary Objectives Key Inclusion/Exclusion Criteria Safety/tolerability assessment and full pharmacokinetic 18-55 years old; overweight or obese (BMI 27-40) characterization. Changes in weight also assessed. Otherwise healthy (no T2D, normal
Slide 17: LIBERATE-1 topline results summary
LIBERATE-1 topline results summary Implant well-tolerated No serious adverse events in the study No clinically meaningful initial burst Encouraging release profile No evidence of dose dumping Potential for durable long-term delivery confirmed Primary study objectives were met: Further NanoPortal cli
Slide 18: Vivani Lead Program: NPM-139
Vivani Lead Program: NPM-139 SLIM : Semaglutide ultra Long-acting IMplant in obesity
Slide 19: NPM-139 clinical and regulatory development: Near-term plan builds on recent wins
NPM-139 clinical and regulatory development: Near-term plan builds on recent wins Milestone Status Reported preclinical proof of concept (~20% weight loss) with NPM-139 August 2025 (semaglutide implant) Received regulatory approval to initiate SLIM-1 clinical trial June 2026 Announced Novo Nordisk a
Slide 20: NPM-139 provides steady preclinical pharmacokinetics
NPM-139 provides steady preclinical 3 pharmacokinetics In vivo pharmacokinetics of NPM-139 configurations in Sprague-Dawley rats. Values are mean ± SE. *n=5 through day 28; two implants removed at Day 28 for characterization, n=3 thereafter. 20
Slide 21: Prototype semaglutide NanoPortal implant demonstrates sustained weight loss and delivery for a full year
Prototype semaglutide NanoPortal implant demonstrates sustained weight loss and delivery for a full year A B explanted devices Prototype NPM-139, prior to PK optimization. In Vivo Normalized semaglutide plasma concentrations remain Pharmacokinetics and Weight loss vs. control in Sprague- measurable
Slide 22: NPM-139 Phase 1 study design: SLIM-1
NPM-139 Phase 1 study design: SLIM-1 Primary Objectives Key Inclusion/Exclusion Criteria Safety/tolerability assessment and pharmacokinetic 18-55 years old; overweight or obese (BMI 27-40) characterization Otherwise healthy (no T2D) Screen and Randomize Treatment (4 Weeks) EOT (~21 days) NPM-139 (se
Slide 23: Proposed NPM-139 Phase 2 study design: SLIM-2
Proposed NPM-139 Phase 2 study design: SLIM-2 Randomize Run-In (20 weeks) Randomized Treatment Period (16 or 24 weeks) Semaglutide Implant Dose 3 Semaglutide Implant Dose 2 2.4 mg Semaglutide Implant Dose 1 1.7 mg 1.0 mg Placebo (sham implant) 0.5 mg Semaglutide 0.25 mg Wegovy® (semaglutide injectio
Slide 24: NanoPortal retatrutide implant provides steady preclinical pharmacokinetics
NanoPortal retatrutide implant provides steady 3 preclinical Prototype NanoPortal Retatrutide Implant, n=12 (through day 28), n=9 (day 28 to 56), n=6 thereafter pharmacokinetics in ongoing study In vivo pharmacokinetics of prototype NanoPortal retatrutide implant in Sprague-Dawley rats in an ongoing
Slide 25: Vivani headquarters and GMP manufacturing facility
Vivani headquarters and GMP manufacturing facility 25
Slide 26: The Vivani executive leadership team
The Vivani executive leadership team Donald Dwyer, MBA Lisa Porter, MD Chief Business Officer Chief Medical Officer ✓ Former Executive Director at AstraZeneca with leadership ✓ Former Chief Medical Officer for Eiger roles in regulatory affairs, drug development, commercial BioPharmaceuticals and Dan
Slide 27: Guaranteed adherence. Better outcomes.
Guaranteed adherence. Better outcomes. Only GLP-1 implant in development for obesity and chronic weight management Convenient once- or twice-yearly dosing expected to address primary GLP-1 market challenges Unique opportunity aligning significant potential benefits for patients, prescribers, payors,
Slide 28: Thank You
Thank You Company Contact: Donald Dwyer, Chief Business Officer info@vivani.com Investor Relations Contact: Jami Taylor, Investor Relations Advisor investors@vivani.com www.vivani.com
Vivani Medical — Investor Presentation (October 2026) on 6ix